Palisade Bio Inc (PALI)

Currency in USD
1.800
-0.190(-9.55%)
Closed·
1.829+0.029(+1.63%)
·
PALI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.8001.990
52 wk Range
0.5302.855
Key Statistics
Prev. Close
1.99
Open
1.98
Day's Range
1.8-1.99
52 wk Range
0.53-2.855
Volume
2.99M
Average Volume (3m)
3.92M
1-Year Change
160.1647%
Book Value / Share
0.87
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PALI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.714
Upside
+439.68%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Palisade Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.714
(+439.68% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Buy25.00+1,288.89%-Maintain13/04/2026
Wolfe Research
Buy7.00+288.89%-New Coverage08/04/2026
Clear Street
Buy12.00+566.67%-Maintain31/03/2026
Stifel
Buy5.00+177.78%-Maintain31/03/2026
H.C. Wainwright
Buy7.00+288.89%-New Coverage26/03/2026

Earnings

Latest Release
20/03/2026
EPS / Forecast
-0.04 / -0.27
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare PALI to Peers and Sector

Metrics to compare
PALI
Peers
Sector
Relationship
P/E Ratio
−19.9x−2.4x−0.6x
PEG Ratio
−0.21−0.090.00
Price/Book
2.6x3.8x2.6x
Price / LTM Sales
-33.6x3.2x
Upside (Analyst Target)
250.0%92.3%48.1%
Fair Value Upside
Unlock7.3%5.8%Unlock

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
12.26M7.32%24.40M
Other Institutional Investors
167.66M92.68%333.64M
Public Companies & Retail Investors
0.000.00%0.00
Total
179.92M100.00%358.04M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Perceptive Advisors LLC7.20%12,050,00023,980
Commodore Capital LP6.84%11,445,00022,776

People Also Watch

2.800
OVID
+2.56%
2.5400
ARTL
-5.22%
2.3900
FBIO
-0.42%
1.640
CRDF
+2.50%
2.130
MBOT
0.00%

FAQ

What Is the Palisade Bio (NASDAQ: PALI) Share Price Today?

The Palisade Bio stock price today is 1.800 USD.

What Stock Exchange Does Palisade Bio (PALI) Trade On?

Palisade Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Palisade Bio?

The stock symbol (also called a 'ticker') for Palisade Bio is "PALI."

What Is the Current Palisade Bio Market Capitalisation?

As of today, Palisade Bio (NASDAQ: PALI) market cap is 303.870M USD.

What Is Palisade Bio's (PALI) Earnings Per Share (TTM)?

The Palisade Bio EPS is currently -0.301 (Trailing Twelve Months).

Is PALI a Buy or Sell From a Technical Analyst Perspective?

Based on today's Palisade Bio moving averages and other technical indicators, the daily buy/sell signal for PALI stock is Strong Sell.

How Many Times Has Palisade Bio Stock Split?

Palisade Bio has split 5 times. (See the PALI stock split history page for full effective split date and price information.)

How Many Employees Does Palisade Bio Have?

Palisade Bio has 14 employees, based on their latest Companies House report.

What is the current trading status of Palisade Bio (NASDAQ: PALI)?

As of 08/05/2026, Palisade Bio (PALI) is trading at a share price of 1.800 USD, with a previous close of 1.990 USD. The stock has fluctuated within a day range of 1.800 USD to 1.990 USD, while its 52-week range spans from 0.530 USD to 2.855 USD.

What Is Palisade Bio (PALI) Price Target According to Analysts?

The average 12-month price target for Palisade Bio is 9.714 USD, with a high estimate of 25 USD and a low estimate of 5 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +439.68% Upside potential.

What Is the PALI Premarket Price?

PALI's last pre-market stock price is 1.966 USD. The pre-market share volume is 9,770.000, and the stock has decreased by -0.024, or -1.210%.

What Is the PALI After Hours Price?

PALI's last after hours stock price is 1.829 USD, the stock has decreased by 0.029, or 1.630%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.